Israel Active

University of Haifa researcher Yifat Segev has discovered a link between dementia and the activity level of a protein called eIF2alpha. Head of Neurobiology Prof. Kobi Rosenblum said that altering the performance of this protein through medication could treat the incurable, progressive disease.

Israel’s MMATech has developed a unique polymer for use in hip replacements, dental implants and other operations. MP-1 is a tough, low-friction polyimide that will preserve implants for longer than their current average lifespan in the body.

(Thanks to Israel21c) Israel’s BioControl Medical is currently testing its CardioFit electrical stimulation device on 200 patients at risk of heart failure at 50 US medical centers. CardioFit already has the CE mark from the European Union.

Irene Pollin, founder and chairman of Sister to Sister, announced her donation at the 100th anniversary celebration of the Hadassah Women’s Zionist Organization of America in Jerusalem. The new cardiovascular wellness institute will counter heart disease - the leading cause of death among women.

The University of Haifa’s tower and the Neve Nof tower on the boardwalk of Bat Yam – the tallest residential building in Israel – were bathed in pink light to remind the public of breast cancer awareness month.

Hatzalah paramedic Arie Jaffe had just finished reading the Torah to celebrate his forthcoming wedding when his emergency (Israeli-made) MIRS device started vibrating. He rushed outside in time to save an elderly congregant who had been run-over whilst crossing the road.

October is National Breast Cancer Awareness Month. Here are some of the many examples of the successful developments from Israel’s Weizmann Institute and current research that could potentially eradicate breast cancer in the future.

Ya'ara Saad, a PhD student at Tel Aviv University, has been growing neuron networks from fruit flies in the laboratory. By measuring electrical activity and synapse development, she is building a platform for testing potential treatments for neuro-degenerative diseases such as Alzheimer’s.

In Harvard’s clinical trial, the NeuroAD system from Israel’s Neuronix not only stopped patients' symptoms from deteriorating, in some cases it actually improved patients' cognitive performance to a greater extent than what is currently available with approved medications.

I’ve reported many of the successful operations performed at Israel’s Save A Child’s Heart organisation on Palestinian Arabs and African children. Here, for the medical community, is an example of the kind of operation that surgeons perform at Wolfson Medical Centre in Holon.